ArticleEnvironment international2025
Novel and legacy per- and polyfluoroalkyl substances in humans: Long-term temporal variability and metabolic perturbations.
Article in Environment international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Associations between pyrethroid insecticide concentrations and dyslipidemia: Findings from the Dongfeng-Tongji cohort.Science advances · 2026Article
- Use of a capillary blood collection device to monitor exposure to per- and polyfluoroalkyl substances (PFAS) in Veterans living in proximity to potential sources of environmental contamination.Journal of exposure science & environmental epidemiology · 2026Article
- Urine-to-Blood Partitioning of Per- and Polyfluoroalkyl Substances in Human Biomonitoring: Implications for Environmental Exposure Analysis and Bioaccumulation Assessment.Molecules (Basel, Switzerland) · 2026Review
- Forever Chemicals, Finite Defenses: PFAS Burden the Liver, Break Mitochondria, and Outpace Modern Regulation.International journal of molecular sciences · 2026Review
- Integrated chemical exposome-metabolome profiling of follicular fluid and associations with fertility outcomes during assisted reproduction.Environment international · 2025Article
- Exposure to Per- and Polyfluoroalkyl Substances (PFASs) in Healthcare: Environmental and Clinical Insights.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
As legacy per- and polyfluoroalkyl substances (PFAS) are phased out, numerous substitutes have emerged, raising concerns about their potential health impacts. Using targeted and untargeted approaches, we evaluated plasma PFAS on an -omic scale, examining temporal variability and associated metabolomic disruptions. A total of 400 blood samples from 200 Sister Study participants (collected in 2007-2008 and 2013-2014) were analyzed using liquid chromatography with high-resolution mass spectrometry. Temporal variability was assessed using Spearman correlations and intraclass correlation coefficients. Network analysis, metabolome-wide association studies, and pathway analysis were used to evaluate the impacts of PFAS mixtures on the human metabolome. We detected 24 legacy PFAS via the targeted approach and 1,802 features annotated as potential PFAS via the untargeted approach (21 confirmed by reference standards). While legacy PFAS demonstrated low temporal variability, novel PFAS, especially those that have increased in abundance over time, demonstrated greater temporal variability. The legacy PFAS mixture was associated with lipid and amino acid metabolism, while other PFAS mixtures consisting of novel PFAS affected a wider range of metabolic pathways in addition to amino and lipid metabolism, such as carbohydrate, cofactor and vitamin, and endocrine metabolism. These findings underscore the need for further research on these novel PFAS and their health effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.